GlassScriptPhysician profile
Rocky L Mcadams
NPI 1740442607
$6,582.63
in general payments reported to CMS, 2019-2025
27 companies · $623 in 2025
The $623 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $358 · 2021: $538 · 2022: $1,378 · 2023: $526 · 2024: $2,734 · 2025: $623.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Long Term Medical Supply Or Device Loan: $2,421 · Food and Beverage: $1,461.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Long Term Medical Supply Or Device Loan | $2,421.28 |
| Food and Beverage | $1,461.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Carl Zeiss Meditec USA, INC. | $2,453.90 | 2023-2024 | Lumera 700 |
| Notal Vision, INC. | $814.27 | 2022 | |
| Alcon Vision LLC | $705.24 | 2019-2025 | Clareon, Unity, Clareon Panoptix Pro |
| Abbvie INC. | $669.72 | 2022-2025 | |
| Aerie Pharmaceuticals, INC. | $265.57 | 2019-2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $237.83 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $230.31 | 2022-2025 | Vyzulta, Xiidra, Miebo |
| Glaukos Corporation | $212.00 | 2019-2022 | |
| Sight Sciences, INC. | $172.89 | 2021-2025 | Omni Surgical System |
| Allergan, INC. | $139.28 | 2020-2022 | |
| Optos, INC. | $92.73 | 2021 | |
| Ziemer USA | $83.35 | 2022 | |
| Rxsight INC | $81.68 | 2023-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Biotissue Holdings INC. | $67.92 | 2019 | |
| Ocular Therapeutix, INC. | $61.89 | 2023-2025 | Dextenza |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $60.44 | 2025 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $34.26 | 2019-2021 | |
| Dompe US, INC. | $29.24 | 2025 | Oxervate |
| Vantage Technology LLC | $27.88 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $24.15 | 2024 | Xdemvy |
| Kala Pharmaceuticals, INC. | $23.70 | 2021 | |
| Eyepoint US, INC. | $18.73 | 2019 | |
| Rayner Intraocular Lenses Limited | $15.94 | 2025 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Horizon Therapeutics Plc | $15.41 | 2023 | Tepezza |
| New World Medical,INC. | $15.05 | 2022 | |
| Omeros Corporation | $14.92 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.33 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocky Mcadams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.